Nomination committee

The members of the nomination committee must safeguard the interests of all shareholders and not unduly disclose what has occurred in the nomination committee’s work.

The duties of the Nomination committee include preparing and drafting of proposals for election and remuneration to the chairman of the board, members of the board of directors, committee members and auditors.

In accordance with the principles for the appointment of the nomination committee of Isofol Medical AB (publ) adopted at the annual general meeting 2026, the nomination committee for the annual general meeting 2027 shall consist of  three members of representatives appointed by the three largest shareholders in the company for the number of votes at September 30, 2026. Another nomination committee member may be appointed by minority shareholders representing at least 10 percent of the votes based on the share register provided by Euroclear Sweden AB or other reliable information. 

The term of office for the nomination committee shall run until a new nomination committee is appointed.

The nomination committee ahead of the AGM 2027 consists of the following members

• Christian Haglund, representing approximately 12.3 percent of the shares and votes,
• Mats Franzén, representing approximately 3.0 percent of the shares and votes,
• Mats-Ola Palm, chairman of the nomination committee, appointed by Hans Enocson representing approximately 2.7 percent of the shares and votes and,
• Lars Lind, appointed by a minority of owners representing approximately 11.0 percent of shares and votes.

The members of the nomination committee are appointed by owners who represent a total of approximately 29.0 percent of the total number of shares and votes in Isofol according to the ownership conditions as of September 30, 2026.

Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: “Isofol’s nomination committee”) or by mail to the following address:

Isofol Medical AB (publ)
Att. Valberedningen
Arvid Wallgrens Backe 20
S-413 46  GOTHENBURG
SWEDEN

Any proposals received by the nomination committee no later than February 28, 2027, was included in the notice and agenda for the Annual General Meeting 2027.

Related documents